Carisma Therapeutics (NASDAQ:CARM) Price Target Cut to $5.00 by Analysts at HC Wainwright

Carisma Therapeutics (NASDAQ:CARM) had its price objective lowered by HC Wainwright from $8.00 to $5.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

CARM opened at $0.85 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $35.29 million, a P/E ratio of -0.54 and a beta of 1.49. The stock has a 50-day moving average price of $0.97 and a 200-day moving average price of $1.10. Carisma Therapeutics has a 12-month low of $0.80 and a 12-month high of $3.16.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). The business had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Equities analysts predict that Carisma Therapeutics will post -1.33 earnings per share for the current fiscal year.

Institutional Trading of Carisma Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after buying an additional 11,200 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Carisma Therapeutics during the second quarter worth about $40,000. Wexford Capital LP grew its stake in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Barclays PLC increased its holdings in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the period. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.